OCGN
Ocugen IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$609.89M
P/E Ratio
—
EPS
$-0.23
Beta
2.81
52W High
$2.73
52W Low
$0.64
50-Day MA
$1.76
200-Day MA
$1.41
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
13.07
PEG Ratio
—
About Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Fundamentals
| Revenue (TTM) | $4.41M |
| Gross Profit (TTM) | $-35.34M |
| EBITDA | $-61.19M |
| Operating Margin | 8559.00% |
| Return on Equity | -777.00% |
| Return on Assets | -63.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-0.04 |
| Price-to-Book | 149.16 |
| Price-to-Sales (TTM) | 138.20 |
| EV/Revenue | 132.96 |
| EV/EBITDA | -1.95 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 54.20% |
| Shares Outstanding | $327.90M |
| Float | $322.70M |
| % Insiders | 2.65% |
| % Institutions | 18.83% |
Analyst Ratings
Consensus ($11.57 target)
1
Strong Buy6
BuyData last updated: 4/9/2026